The internalization eventually results in efficient lysosomal degradation of HER2, which in tumours driven by HER2 homo‐ or heterodimers most likely will give therapy with antibody mixtures an advantage compared to therapy with single monoclonal antibodies. Here, ERBB2 is linked to neoplasm.